The historic healthcare reform legislation that was signed by U.S. President Barack Obama yesterday (23rd March) will be an obvious boon to big pharmaceutical companies and hospitals, which will eventually have access to more than 30 million new customers covered under the bill. But how will the bill affect smaller companies and academics? __The Scientist__ asked linkurl:Kenneth Kaitin,; professor of medicine and director of the Tufts Center for the Study of Drug Development.
Kenneth Kaitin
Image courtesy of the Tufts Center
for the Study of Drug Development
__The Scientist__: What do you think the effect of the passage of the healthcare reform legislation will be on the biotech industry? __Kenneth Kaitin__: There was the provision in the bill that affords 12 years of market exclusivity for branded biopharmaceutical products, which is a substantial and very critical guarantee that companies that develop biopharmaceutical products would have adequate amount of...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?